CSL is making about 30 million doses of the Oxford-AstraZeneca vaccine despite clinical trials continuingEarly production of a yet to be approved vaccine is a high-risk strategy that could save thousands of livesThe company, CSL, is making about 30 million doses of the Oxford-AstraZeneca vaccine despite it still going through phase-three clinical trials.
While there's still a way to go, CSL's chief scientific officer Andrew Nash says the company is "hopeful" the gamble will pay off. "So it will deliver and manufacture the vaccine antigen to the person that's been vaccinated, as distinct from some of the other vaccine technologies where we actually make the vaccine antigen known as the spike protein … outside the body, then we administer that to the recipient of the vaccine.""It is extremely unusual to do so," Professor Dawson said.
There's also a risk that people will be reluctant to get it if it seems that the process has been rushed. There's enough people who are already distrustful of tried and proven vaccines- a new one which is perceived to have been rushed thru to production could be a tough sell
Note, the risk discussed in the article is entirely a financial one, not a health risk.
What's the 'high' risk? Aren't the government underwriting the costs?
Fascinating, hope to God this vax has no detrimental health effects